teokb989的个人主页 - 老虎社区

teokb989

teokb989

暂无个人介绍

IP属地：未知

40关注

6粉丝

0主题

0勋章

2021-03-29

Watch out[惊讶]

Bank stocks drop after Archegos Capital collapses

2021-03-22

[保佑] [思考]

抱歉，原内容已删除

2021-03-19

[财迷]

Bank stocks just hit their highest level since 2007. Two traders on when to buy in

2021-03-19

[得意]

Palantir: Rally On

2021-03-18

$Check-Cap(CHEK)$[喷血] [喷血] [喷血]

2021-02-23

[强]

BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3574494955430053,"uuid":"3574494955430053","gmtCreate":1611401137079,"gmtModify":1704447478194,"name":"teokb989","pinyin":"teokb989","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":40,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":355319929,"gmtCreate":1617028029861,"gmtModify":1634523037491,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Watch out[惊讶]&nbsp;","listText":"Watch out[惊讶]&nbsp;","text":"Watch out[惊讶]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355319929","repostId":"1180199356","repostType":4,"repost":{"id":"1180199356","pubTimestamp":1617025247,"share":"https://www.laohu8.com/m/news/1180199356?lang=&edition=full","pubTime":"2021-03-29 21:40","market":"us","language":"en","title":"Bank stocks drop after Archegos Capital collapses","url":"https://stock-news.laohu8.com/highlight/detail?id=1180199356","media":"seekingalpha","summary":"Some of the biggest global banks drop in market trading after Archegos Capital, the family office ru","content":"<p>Some of the biggest global banks drop in market trading after Archegos Capital, the family office run by Bill Hwang,wasforced to liquidate, putting the banks in danger of losing billions of dollars.</p><p>Credit Suisse&nbsp;sinks 13%, Nomura&nbsp;slides 13%, Goldman Sachs&nbsp;drops 1%, and Morgan Stanley&nbsp;falls 2.78%, Deutsche Bank&nbsp;dips 2.96%.</p><p><img src=\"https://static.tigerbbs.com/467f28f9b672edc77c3cf438b196dccb\" tg-width=\"279\" tg-height=\"202\" referrerpolicy=\"no-referrer\"></p><p>While it didn't name the client, Credit Suisse&nbsp;warnedinvestors of&nbsp; a \"significant loss\" because it was forced to exit positions after \"a significant U.S.-based hedge fund defaulted on margin calls made last week\" made by CS and a number of other banks, the company said.</p><p>BofA Securities analyst Alastair Ryan downgraded CS to Neutral and reduced his 2021 forecast for the bank and price target due to the losses on the liquidation. \"We believe its capital cushion has likely been reduced to the point where its buyback is directly affected,\" Ryan wrote in a note to clients. (Updated at 7:45 AM ET.)</p><p>Nomura also said it mayincur a significant lossarising from transactions with a U.S. client; it's still calculating its possible loss from the event andestimates the claimagainst the client at ~$2B.</p><p>Morgan Stanley (MS), Goldman Sachs (GS), and Deutsche Bank (DB) are also reported to have been involved. MS and GS didn't immediately respond to request for comment.</p><p>Also see,ViacomCBS block of 45M shares was being offered by Morgan Stanley on Sunday</p><p>Earlier,Morgan Stanley had 'disturbing' widening in credit default swaps late last week, expert says.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bank stocks drop after Archegos Capital collapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBank stocks drop after Archegos Capital collapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-29 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3677088-bank-stocks-drop-after-archegos-capital-collapses><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some of the biggest global banks drop in market trading after Archegos Capital, the family office run by Bill Hwang,wasforced to liquidate, putting the banks in danger of losing billions of dollars....</p>\n\n<a href=\"https://seekingalpha.com/news/3677088-bank-stocks-drop-after-archegos-capital-collapses\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/69af882c29a3ff047224139fe1096d17","relate_stocks":{"MS":"摩根士丹利","NMR":"野村控股","DB":"德意志银行","GS":"高盛"},"source_url":"https://seekingalpha.com/news/3677088-bank-stocks-drop-after-archegos-capital-collapses","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1180199356","content_text":"Some of the biggest global banks drop in market trading after Archegos Capital, the family office run by Bill Hwang,wasforced to liquidate, putting the banks in danger of losing billions of dollars.Credit Suisse sinks 13%, Nomura slides 13%, Goldman Sachs drops 1%, and Morgan Stanley falls 2.78%, Deutsche Bank dips 2.96%.While it didn't name the client, Credit Suisse warnedinvestors of  a \"significant loss\" because it was forced to exit positions after \"a significant U.S.-based hedge fund defaulted on margin calls made last week\" made by CS and a number of other banks, the company said.BofA Securities analyst Alastair Ryan downgraded CS to Neutral and reduced his 2021 forecast for the bank and price target due to the losses on the liquidation. \"We believe its capital cushion has likely been reduced to the point where its buyback is directly affected,\" Ryan wrote in a note to clients. (Updated at 7:45 AM ET.)Nomura also said it mayincur a significant lossarising from transactions with a U.S. client; it's still calculating its possible loss from the event andestimates the claimagainst the client at ~$2B.Morgan Stanley (MS), Goldman Sachs (GS), and Deutsche Bank (DB) are also reported to have been involved. MS and GS didn't immediately respond to request for comment.Also see,ViacomCBS block of 45M shares was being offered by Morgan Stanley on SundayEarlier,Morgan Stanley had 'disturbing' widening in credit default swaps late last week, expert says.","news_type":1},"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":353002920,"gmtCreate":1616427559060,"gmtModify":1634525858287,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[保佑]&nbsp;[思考]&nbsp;","listText":"[保佑]&nbsp;[思考]&nbsp;","text":"[保佑] [思考]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/353002920","repostId":"353000812","repostType":1,"isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":350302760,"gmtCreate":1616157290050,"gmtModify":1634526962300,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/350302760","repostId":"1184711133","repostType":4,"repost":{"id":"1184711133","pubTimestamp":1616153616,"share":"https://www.laohu8.com/m/news/1184711133?lang=&edition=full","pubTime":"2021-03-19 19:33","market":"us","language":"en","title":"Bank stocks just hit their highest level since 2007. Two traders on when to buy in","url":"https://stock-news.laohu8.com/highlight/detail?id=1184711133","media":"cnbc","summary":"Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s see","content":"<div>\n<p>Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s seen since 2007 in Thursday’s trading, fueled by theyield on the U.S. 10-year Treasury noterising to 14...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bank stocks just hit their highest level since 2007. Two traders on when to buy in</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBank stocks just hit their highest level since 2007. Two traders on when to buy in\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-19 19:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s seen since 2007 in Thursday’s trading, fueled by theyield on the U.S. 10-year Treasury noterising to 14...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1184711133","content_text":"Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s seen since 2007 in Thursday’s trading, fueled by theyield on the U.S. 10-year Treasury noterising to 14-month highs. Themovescame despite theFederal Reserve’s Wednesday statementthat it would keep interest rates near zero through at least 2023.\nTwo traders told CNBC on Thursday that while bank stocks are attractive over the long term, it’s worth waiting for a pullback to buy in.\n“Even though I am very bullish on a long-term basis on the bank stocks ... they are getting quite overbought and so is the yield on the 10-year note,” Matt Maley, chief market strategist at Miller Tabak, said on CNBC’s“Trading Nation.”\nThe KBE’s relative strength index — a momentum indicator frequented by chart analysts — is the most overbought it’s been in three years, which means “it’s getting ripe for a bit of a pullback,” Maley said.\nTo make things more dire for investors, the 10-year yield is the most overbought it has been since 1994, the strategist warned.\n“I currently believe that the Fed, even though they’re talking about doubling down on being dovish on short-term rates, they’re actually more hawkish on long-term rates because they’re willing to let inflation run higher,” Maley said.\n“That means … rates will go higher over time, but the short-term technical picture is telling me they should pull back a little bit,” he said. “So, I wouldn’t jump back into these bank stocks at these levels. I’d let them come back in and add to positions after that takes place.”\nWhen that pullback comes, three stocks will be particularly good opportunities, Nancy Tengler, Laffer Tengler Investments’ chief investment officer, said in the same “Trading Nation” interview.\n“We went overweight [banks] in the … late summer and we really emphasized companies that had exposure to interest rates, but also had diversification in terms of noninterest income,” Tengler said.\nHer firm’s largest holdings in the space areJPMorgan,PNC FinancialandGoldman Sachs, which is also part of Laffer Tengler’s “12 best ideas” portfolio.\n“Though I agree with Matt — the stocks have run hard, so, you don’t need to jump in with both feet — on a fundamental basis, these companies are looking better and better as time goes on,” Tengler said.\n“I thinkthe Fedmay be letting the bond market do its work for it in steepening the yield curve,” she said. “They keep short rates very short and are willing to let the yield curve steepen. And so, while we think the stocks are somewhat expensive on valuation, they’re still attractive in our work and we’re going to continue to pick away at them on weakness.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":327565964,"gmtCreate":1616111142558,"gmtModify":1634527217156,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意]&nbsp;","listText":"[得意]&nbsp;","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/327565964","repostId":"1140777123","repostType":4,"repost":{"id":"1140777123","pubTimestamp":1616053819,"share":"https://www.laohu8.com/m/news/1140777123?lang=&edition=full","pubTime":"2021-03-18 15:50","market":"us","language":"en","title":"Palantir: Rally On","url":"https://stock-news.laohu8.com/highlight/detail?id=1140777123","media":"seekingalpha","summary":"Summary\n\nPalantir's short interest declined by almost 27% in the last cycle.\nThe stock seems to be f","content":"<p><b>Summary</b></p>\n<ul>\n <li>Palantir's short interest declined by almost 27% in the last cycle.</li>\n <li>The stock seems to be forming a bottom, before it starts rallying again.</li>\n <li>Investors should avoid the fear, uncertainty and doubt, and remain invested in the name.</li>\n</ul>\n<p>Palantir's (PLTR) shares are down 40% in value over the past two months and investment forums are rife with debates on the longevity of this price correction. Some bears are forecasting its shares to fall by another 50% in the near future but the reality may not be so bleak. Latest data actually reveals that short interest in the stock dropped by 26.7% in the last reporting cycle. This suggests that the stock is in the process of forming a bottom and it may not depreciate much, which should come across as an encouraging news for long-side Palantir investors. Let's take a closer look at it all.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/84aaa95ba29871bd3ef8c8b179aa611e\" tg-width=\"1280\" tg-height=\"853\"><span>Source: Palantir website</span></p>\n<p><b>The dropping short interest</b></p>\n<p>For the uninitiated, short interest is essentially the aggregate number of short positions that are open and yet to be covered. A sharp rise in the metric indicates that market participants have stacked up short positions in a particular stock, in order to profit from a potential price correction. Conversely, a sharp drop in the metric suggests that market participants have wound up their short positions as they perceive the stock to be fairly or undervalued, with limited downside potential. So, altogether, short interest helps us in gauging the Street's ever-evolving sentiment relating to any given stock.</p>\n<p>As far as Palantir is concerned, its short interest dropped by a massive 26.7% sequentially and stood at 56.43 million at the end of the last cycle. For the record, the last short interest cycle spanned from mid-February to February-end and the data was disseminated only afew daysago. To put things in perspective, the company has about 1.75 billion shares outstanding which means that a mere 3% of its entire share total stood shorted.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/11e73699ec600a696859f5389bf092a5\" tg-width=\"222\" tg-height=\"662\"><span>Source: WSJ</span></p>\n<p>This is a miniscule amount of shorting activity. I say this because companies that are surrounded by bearish narratives and have uncertain future prospects, generally attract speculative short-side bets in far greater numbers. I personally view short interest to be considerably high if it amounts to 20% or more of a company's total shares outstanding. But Palantir seems to be thinly shorted by this benchmark. For all we know, its ~3% short interest figure could be comprised of hedging-related bets with the sole purpose of minimizing volatility risk.</p>\n<p>I looked at other software stocks to get a different perspective but to no avail. Out of the 47 stocks in my study, 55% saw their short interest increase while 45% of the stocks registered a decline in their short interest. This more or less even split suggests that market participants wound up their short positions in Palantir largely because of their assessment of the stock and its underlying future prospects, rather than this short covering being driven by industry trends. Besides, shorting activity in Palantir was below industry average, thereby corroborating my view that it's a thinly shorted stock.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f4488d2e553eb79612e74a0b3aa05b72\" tg-width=\"348\" tg-height=\"823\"><span>Data from individual quote pages on wsj.com</span></p>\n<p>This begs the question - why aren't market participants shorting Palantir in the first place?</p>\n<p><b>Cautious for good reason</b></p>\n<p>For starters, Palantir's shares corrected by about 45% within February itself as a knee-jerk reaction to its Q4 results. This provided large gains for short-side market participants in a short time span, prompting them to unwind their positions and book healthy profits. So, that's one of the reasons why Palantir's short interest declined in the last cycle.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/81236e9babe568b807c6641dac7fea6e\" tg-width=\"635\" tg-height=\"433\"><span>Data by YCharts</span></p>\n<p>Besides, with this correction, Palantir's shares are now trading at relatively modest valuation multiples. Per YCharts, its price-to-sales multiple has dropped from a steep 40x in January to a much more reasonable 29.4x at the time of this writing, and the metric is quite close to its 52-week low of around 24x. This suggests that the stock is close to its rock-bottom prices and it might have limited downside potential going forward. So, short-side market participants may be best served by booking profits in Palantir and reallocating their capital in other, more lucrative, trade setups.</p>\n<p>Also, I explained in my previous article that Palantir is transitioning to a recurring payment model. The company used to charge its customers in advance for multi-year agreements, but it's now going to bill customers on recurring intervals, like a software-as-a-service model but with some contract cancellation clauses. We won't be covering the same points again in this article but the crux of it is that this move is likely going to boost Palantir's commercial revenues. This growth prospect makes it a risky move to short Palantir's shares for the time being, at least.</p>\n<p>Also, Palantir, historically, hasn't been too focused on its sales effort. Its&nbsp;10K reads:</p>\n<blockquote>\n …our headcount has grown from 313 full-time employees as of December 31, 2010 to 2,439 full-time employees as of December 31, 2020…\n <b>Our sales force remains relatively small, at about 3% of our total headcount.</b>\n</blockquote>\n<p>I thinkit's needless to say but having an understaffed sales team is bound to limit new order and sales growth. There just wouldn't be enough sales personnel to aggressively chase and convert leads.</p>\n<p>But Palantir's management seems to be now laser-focused on remedying this oversight by significantly ramping up their sales team. They disclosed last month that the company is gaining access to IBM's&nbsp;2,500 sellers, which is dramatically up from the current 30 sellers. Its management also noted in their&nbsp;Q4 earnings call&nbsp;that they \"expect to add triple digit head count to our sales function this year\".</p>\n<p>This heightened focus on revamping the sales function, and their transition to a more customer friendly payment model, is likely going to generate new deals for Palantir and boost its sales along the way. So, in my view, it's risky move to remain short on Palantir for an extended period of time.</p>\n<p><b>Final Thoughts</b></p>\n<p>If bears truly had a legitimate argument against Palantir, they would have actively shorted the name in a bid to profit off of a potential price correction and we'd have seen a rapid rise in its short interest. But that did not happen and Palantir's short interest dropped significantly instead. This suggests that market participants perceive the stock to be fairly or undervalued, and that the stock may have limited downside potential from the current levels. So, I would recommend Palantir's long-side investors to ignore the fear, uncertainty and doubt, and remain long on the name. Its intensifying sales push and reduced customer resistance with flexible payment plans, are likely going to drive its overall growth going forward. Good Luck!</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Rally On</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Rally On\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 15:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4414020-palantir-rally-on><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPalantir's short interest declined by almost 27% in the last cycle.\nThe stock seems to be forming a bottom, before it starts rallying again.\nInvestors should avoid the fear, uncertainty and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4414020-palantir-rally-on\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4414020-palantir-rally-on","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140777123","content_text":"Summary\n\nPalantir's short interest declined by almost 27% in the last cycle.\nThe stock seems to be forming a bottom, before it starts rallying again.\nInvestors should avoid the fear, uncertainty and doubt, and remain invested in the name.\n\nPalantir's (PLTR) shares are down 40% in value over the past two months and investment forums are rife with debates on the longevity of this price correction. Some bears are forecasting its shares to fall by another 50% in the near future but the reality may not be so bleak. Latest data actually reveals that short interest in the stock dropped by 26.7% in the last reporting cycle. This suggests that the stock is in the process of forming a bottom and it may not depreciate much, which should come across as an encouraging news for long-side Palantir investors. Let's take a closer look at it all.\nSource: Palantir website\nThe dropping short interest\nFor the uninitiated, short interest is essentially the aggregate number of short positions that are open and yet to be covered. A sharp rise in the metric indicates that market participants have stacked up short positions in a particular stock, in order to profit from a potential price correction. Conversely, a sharp drop in the metric suggests that market participants have wound up their short positions as they perceive the stock to be fairly or undervalued, with limited downside potential. So, altogether, short interest helps us in gauging the Street's ever-evolving sentiment relating to any given stock.\nAs far as Palantir is concerned, its short interest dropped by a massive 26.7% sequentially and stood at 56.43 million at the end of the last cycle. For the record, the last short interest cycle spanned from mid-February to February-end and the data was disseminated only afew daysago. To put things in perspective, the company has about 1.75 billion shares outstanding which means that a mere 3% of its entire share total stood shorted.\nSource: WSJ\nThis is a miniscule amount of shorting activity. I say this because companies that are surrounded by bearish narratives and have uncertain future prospects, generally attract speculative short-side bets in far greater numbers. I personally view short interest to be considerably high if it amounts to 20% or more of a company's total shares outstanding. But Palantir seems to be thinly shorted by this benchmark. For all we know, its ~3% short interest figure could be comprised of hedging-related bets with the sole purpose of minimizing volatility risk.\nI looked at other software stocks to get a different perspective but to no avail. Out of the 47 stocks in my study, 55% saw their short interest increase while 45% of the stocks registered a decline in their short interest. This more or less even split suggests that market participants wound up their short positions in Palantir largely because of their assessment of the stock and its underlying future prospects, rather than this short covering being driven by industry trends. Besides, shorting activity in Palantir was below industry average, thereby corroborating my view that it's a thinly shorted stock.\nData from individual quote pages on wsj.com\nThis begs the question - why aren't market participants shorting Palantir in the first place?\nCautious for good reason\nFor starters, Palantir's shares corrected by about 45% within February itself as a knee-jerk reaction to its Q4 results. This provided large gains for short-side market participants in a short time span, prompting them to unwind their positions and book healthy profits. So, that's one of the reasons why Palantir's short interest declined in the last cycle.\nData by YCharts\nBesides, with this correction, Palantir's shares are now trading at relatively modest valuation multiples. Per YCharts, its price-to-sales multiple has dropped from a steep 40x in January to a much more reasonable 29.4x at the time of this writing, and the metric is quite close to its 52-week low of around 24x. This suggests that the stock is close to its rock-bottom prices and it might have limited downside potential going forward. So, short-side market participants may be best served by booking profits in Palantir and reallocating their capital in other, more lucrative, trade setups.\nAlso, I explained in my previous article that Palantir is transitioning to a recurring payment model. The company used to charge its customers in advance for multi-year agreements, but it's now going to bill customers on recurring intervals, like a software-as-a-service model but with some contract cancellation clauses. We won't be covering the same points again in this article but the crux of it is that this move is likely going to boost Palantir's commercial revenues. This growth prospect makes it a risky move to short Palantir's shares for the time being, at least.\nAlso, Palantir, historically, hasn't been too focused on its sales effort. Its 10K reads:\n\n …our headcount has grown from 313 full-time employees as of December 31, 2010 to 2,439 full-time employees as of December 31, 2020…\n Our sales force remains relatively small, at about 3% of our total headcount.\n\nI thinkit's needless to say but having an understaffed sales team is bound to limit new order and sales growth. There just wouldn't be enough sales personnel to aggressively chase and convert leads.\nBut Palantir's management seems to be now laser-focused on remedying this oversight by significantly ramping up their sales team. They disclosed last month that the company is gaining access to IBM's 2,500 sellers, which is dramatically up from the current 30 sellers. Its management also noted in their Q4 earnings call that they \"expect to add triple digit head count to our sales function this year\".\nThis heightened focus on revamping the sales function, and their transition to a more customer friendly payment model, is likely going to generate new deals for Palantir and boost its sales along the way. So, in my view, it's risky move to remain short on Palantir for an extended period of time.\nFinal Thoughts\nIf bears truly had a legitimate argument against Palantir, they would have actively shorted the name in a bid to profit off of a potential price correction and we'd have seen a rapid rise in its short interest. But that did not happen and Palantir's short interest dropped significantly instead. This suggests that market participants perceive the stock to be fairly or undervalued, and that the stock may have limited downside potential from the current levels. So, I would recommend Palantir's long-side investors to ignore the fear, uncertainty and doubt, and remain long on the name. Its intensifying sales push and reduced customer resistance with flexible payment plans, are likely going to drive its overall growth going forward. Good Luck!","news_type":1},"isVote":1,"tweetType":1,"viewCount":432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":324703657,"gmtCreate":1616028720279,"gmtModify":1703496539323,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHEK\">$Check-Cap(CHEK)$</a>[喷血]&nbsp;[喷血]&nbsp;[喷血]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHEK\">$Check-Cap(CHEK)$</a>[喷血]&nbsp;[喷血]&nbsp;[喷血]&nbsp;","text":"$Check-Cap(CHEK)$[喷血] [喷血] [喷血]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/324703657","isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":363900841,"gmtCreate":1614088374883,"gmtModify":1634551229883,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363900841","repostId":"2113335786","repostType":2,"repost":{"id":"2113335786","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614083671,"share":"https://www.laohu8.com/m/news/2113335786?lang=&edition=full","pubTime":"2021-02-23 20:34","market":"us","language":"en","title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","media":"Reuters","summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","content":"<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-23 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2113335786","content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":324703657,"gmtCreate":1616028720279,"gmtModify":1703496539323,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CHEK\">$Check-Cap(CHEK)$</a>[喷血]&nbsp;[喷血]&nbsp;[喷血]&nbsp;","listText":"<a href=\"https://laohu8.com/S/CHEK\">$Check-Cap(CHEK)$</a>[喷血]&nbsp;[喷血]&nbsp;[喷血]&nbsp;","text":"$Check-Cap(CHEK)$[喷血] [喷血] [喷血]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/324703657","isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":350302760,"gmtCreate":1616157290050,"gmtModify":1634526962300,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/350302760","repostId":"1184711133","repostType":4,"repost":{"id":"1184711133","pubTimestamp":1616153616,"share":"https://www.laohu8.com/m/news/1184711133?lang=&edition=full","pubTime":"2021-03-19 19:33","market":"us","language":"en","title":"Bank stocks just hit their highest level since 2007. Two traders on when to buy in","url":"https://stock-news.laohu8.com/highlight/detail?id=1184711133","media":"cnbc","summary":"Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s see","content":"<div>\n<p>Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s seen since 2007 in Thursday’s trading, fueled by theyield on the U.S. 10-year Treasury noterising to 14...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bank stocks just hit their highest level since 2007. Two traders on when to buy in</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBank stocks just hit their highest level since 2007. Two traders on when to buy in\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-19 19:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s seen since 2007 in Thursday’s trading, fueled by theyield on the U.S. 10-year Treasury noterising to 14...</p>\n\n<a href=\"https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/03/19/bank-stocks-just-hit-their-highest-level-since-2007-when-to-buy-in.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1184711133","content_text":"Bank stocks are breaking out in a big way.\nTheSPDR S&P Bank ETF(KBE) hit the highest levels it’s seen since 2007 in Thursday’s trading, fueled by theyield on the U.S. 10-year Treasury noterising to 14-month highs. Themovescame despite theFederal Reserve’s Wednesday statementthat it would keep interest rates near zero through at least 2023.\nTwo traders told CNBC on Thursday that while bank stocks are attractive over the long term, it’s worth waiting for a pullback to buy in.\n“Even though I am very bullish on a long-term basis on the bank stocks ... they are getting quite overbought and so is the yield on the 10-year note,” Matt Maley, chief market strategist at Miller Tabak, said on CNBC’s“Trading Nation.”\nThe KBE’s relative strength index — a momentum indicator frequented by chart analysts — is the most overbought it’s been in three years, which means “it’s getting ripe for a bit of a pullback,” Maley said.\nTo make things more dire for investors, the 10-year yield is the most overbought it has been since 1994, the strategist warned.\n“I currently believe that the Fed, even though they’re talking about doubling down on being dovish on short-term rates, they’re actually more hawkish on long-term rates because they’re willing to let inflation run higher,” Maley said.\n“That means … rates will go higher over time, but the short-term technical picture is telling me they should pull back a little bit,” he said. “So, I wouldn’t jump back into these bank stocks at these levels. I’d let them come back in and add to positions after that takes place.”\nWhen that pullback comes, three stocks will be particularly good opportunities, Nancy Tengler, Laffer Tengler Investments’ chief investment officer, said in the same “Trading Nation” interview.\n“We went overweight [banks] in the … late summer and we really emphasized companies that had exposure to interest rates, but also had diversification in terms of noninterest income,” Tengler said.\nHer firm’s largest holdings in the space areJPMorgan,PNC FinancialandGoldman Sachs, which is also part of Laffer Tengler’s “12 best ideas” portfolio.\n“Though I agree with Matt — the stocks have run hard, so, you don’t need to jump in with both feet — on a fundamental basis, these companies are looking better and better as time goes on,” Tengler said.\n“I thinkthe Fedmay be letting the bond market do its work for it in steepening the yield curve,” she said. “They keep short rates very short and are willing to let the yield curve steepen. And so, while we think the stocks are somewhat expensive on valuation, they’re still attractive in our work and we’re going to continue to pick away at them on weakness.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":477,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":327565964,"gmtCreate":1616111142558,"gmtModify":1634527217156,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[得意]&nbsp;","listText":"[得意]&nbsp;","text":"[得意]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/327565964","repostId":"1140777123","repostType":4,"repost":{"id":"1140777123","pubTimestamp":1616053819,"share":"https://www.laohu8.com/m/news/1140777123?lang=&edition=full","pubTime":"2021-03-18 15:50","market":"us","language":"en","title":"Palantir: Rally On","url":"https://stock-news.laohu8.com/highlight/detail?id=1140777123","media":"seekingalpha","summary":"Summary\n\nPalantir's short interest declined by almost 27% in the last cycle.\nThe stock seems to be f","content":"<p><b>Summary</b></p>\n<ul>\n <li>Palantir's short interest declined by almost 27% in the last cycle.</li>\n <li>The stock seems to be forming a bottom, before it starts rallying again.</li>\n <li>Investors should avoid the fear, uncertainty and doubt, and remain invested in the name.</li>\n</ul>\n<p>Palantir's (PLTR) shares are down 40% in value over the past two months and investment forums are rife with debates on the longevity of this price correction. Some bears are forecasting its shares to fall by another 50% in the near future but the reality may not be so bleak. Latest data actually reveals that short interest in the stock dropped by 26.7% in the last reporting cycle. This suggests that the stock is in the process of forming a bottom and it may not depreciate much, which should come across as an encouraging news for long-side Palantir investors. Let's take a closer look at it all.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/84aaa95ba29871bd3ef8c8b179aa611e\" tg-width=\"1280\" tg-height=\"853\"><span>Source: Palantir website</span></p>\n<p><b>The dropping short interest</b></p>\n<p>For the uninitiated, short interest is essentially the aggregate number of short positions that are open and yet to be covered. A sharp rise in the metric indicates that market participants have stacked up short positions in a particular stock, in order to profit from a potential price correction. Conversely, a sharp drop in the metric suggests that market participants have wound up their short positions as they perceive the stock to be fairly or undervalued, with limited downside potential. So, altogether, short interest helps us in gauging the Street's ever-evolving sentiment relating to any given stock.</p>\n<p>As far as Palantir is concerned, its short interest dropped by a massive 26.7% sequentially and stood at 56.43 million at the end of the last cycle. For the record, the last short interest cycle spanned from mid-February to February-end and the data was disseminated only afew daysago. To put things in perspective, the company has about 1.75 billion shares outstanding which means that a mere 3% of its entire share total stood shorted.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/11e73699ec600a696859f5389bf092a5\" tg-width=\"222\" tg-height=\"662\"><span>Source: WSJ</span></p>\n<p>This is a miniscule amount of shorting activity. I say this because companies that are surrounded by bearish narratives and have uncertain future prospects, generally attract speculative short-side bets in far greater numbers. I personally view short interest to be considerably high if it amounts to 20% or more of a company's total shares outstanding. But Palantir seems to be thinly shorted by this benchmark. For all we know, its ~3% short interest figure could be comprised of hedging-related bets with the sole purpose of minimizing volatility risk.</p>\n<p>I looked at other software stocks to get a different perspective but to no avail. Out of the 47 stocks in my study, 55% saw their short interest increase while 45% of the stocks registered a decline in their short interest. This more or less even split suggests that market participants wound up their short positions in Palantir largely because of their assessment of the stock and its underlying future prospects, rather than this short covering being driven by industry trends. Besides, shorting activity in Palantir was below industry average, thereby corroborating my view that it's a thinly shorted stock.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f4488d2e553eb79612e74a0b3aa05b72\" tg-width=\"348\" tg-height=\"823\"><span>Data from individual quote pages on wsj.com</span></p>\n<p>This begs the question - why aren't market participants shorting Palantir in the first place?</p>\n<p><b>Cautious for good reason</b></p>\n<p>For starters, Palantir's shares corrected by about 45% within February itself as a knee-jerk reaction to its Q4 results. This provided large gains for short-side market participants in a short time span, prompting them to unwind their positions and book healthy profits. So, that's one of the reasons why Palantir's short interest declined in the last cycle.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/81236e9babe568b807c6641dac7fea6e\" tg-width=\"635\" tg-height=\"433\"><span>Data by YCharts</span></p>\n<p>Besides, with this correction, Palantir's shares are now trading at relatively modest valuation multiples. Per YCharts, its price-to-sales multiple has dropped from a steep 40x in January to a much more reasonable 29.4x at the time of this writing, and the metric is quite close to its 52-week low of around 24x. This suggests that the stock is close to its rock-bottom prices and it might have limited downside potential going forward. So, short-side market participants may be best served by booking profits in Palantir and reallocating their capital in other, more lucrative, trade setups.</p>\n<p>Also, I explained in my previous article that Palantir is transitioning to a recurring payment model. The company used to charge its customers in advance for multi-year agreements, but it's now going to bill customers on recurring intervals, like a software-as-a-service model but with some contract cancellation clauses. We won't be covering the same points again in this article but the crux of it is that this move is likely going to boost Palantir's commercial revenues. This growth prospect makes it a risky move to short Palantir's shares for the time being, at least.</p>\n<p>Also, Palantir, historically, hasn't been too focused on its sales effort. Its&nbsp;10K reads:</p>\n<blockquote>\n …our headcount has grown from 313 full-time employees as of December 31, 2010 to 2,439 full-time employees as of December 31, 2020…\n <b>Our sales force remains relatively small, at about 3% of our total headcount.</b>\n</blockquote>\n<p>I thinkit's needless to say but having an understaffed sales team is bound to limit new order and sales growth. There just wouldn't be enough sales personnel to aggressively chase and convert leads.</p>\n<p>But Palantir's management seems to be now laser-focused on remedying this oversight by significantly ramping up their sales team. They disclosed last month that the company is gaining access to IBM's&nbsp;2,500 sellers, which is dramatically up from the current 30 sellers. Its management also noted in their&nbsp;Q4 earnings call&nbsp;that they \"expect to add triple digit head count to our sales function this year\".</p>\n<p>This heightened focus on revamping the sales function, and their transition to a more customer friendly payment model, is likely going to generate new deals for Palantir and boost its sales along the way. So, in my view, it's risky move to remain short on Palantir for an extended period of time.</p>\n<p><b>Final Thoughts</b></p>\n<p>If bears truly had a legitimate argument against Palantir, they would have actively shorted the name in a bid to profit off of a potential price correction and we'd have seen a rapid rise in its short interest. But that did not happen and Palantir's short interest dropped significantly instead. This suggests that market participants perceive the stock to be fairly or undervalued, and that the stock may have limited downside potential from the current levels. So, I would recommend Palantir's long-side investors to ignore the fear, uncertainty and doubt, and remain long on the name. Its intensifying sales push and reduced customer resistance with flexible payment plans, are likely going to drive its overall growth going forward. Good Luck!</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir: Rally On</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir: Rally On\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-18 15:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4414020-palantir-rally-on><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nPalantir's short interest declined by almost 27% in the last cycle.\nThe stock seems to be forming a bottom, before it starts rallying again.\nInvestors should avoid the fear, uncertainty and ...</p>\n\n<a href=\"https://seekingalpha.com/article/4414020-palantir-rally-on\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://seekingalpha.com/article/4414020-palantir-rally-on","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1140777123","content_text":"Summary\n\nPalantir's short interest declined by almost 27% in the last cycle.\nThe stock seems to be forming a bottom, before it starts rallying again.\nInvestors should avoid the fear, uncertainty and doubt, and remain invested in the name.\n\nPalantir's (PLTR) shares are down 40% in value over the past two months and investment forums are rife with debates on the longevity of this price correction. Some bears are forecasting its shares to fall by another 50% in the near future but the reality may not be so bleak. Latest data actually reveals that short interest in the stock dropped by 26.7% in the last reporting cycle. This suggests that the stock is in the process of forming a bottom and it may not depreciate much, which should come across as an encouraging news for long-side Palantir investors. Let's take a closer look at it all.\nSource: Palantir website\nThe dropping short interest\nFor the uninitiated, short interest is essentially the aggregate number of short positions that are open and yet to be covered. A sharp rise in the metric indicates that market participants have stacked up short positions in a particular stock, in order to profit from a potential price correction. Conversely, a sharp drop in the metric suggests that market participants have wound up their short positions as they perceive the stock to be fairly or undervalued, with limited downside potential. So, altogether, short interest helps us in gauging the Street's ever-evolving sentiment relating to any given stock.\nAs far as Palantir is concerned, its short interest dropped by a massive 26.7% sequentially and stood at 56.43 million at the end of the last cycle. For the record, the last short interest cycle spanned from mid-February to February-end and the data was disseminated only afew daysago. To put things in perspective, the company has about 1.75 billion shares outstanding which means that a mere 3% of its entire share total stood shorted.\nSource: WSJ\nThis is a miniscule amount of shorting activity. I say this because companies that are surrounded by bearish narratives and have uncertain future prospects, generally attract speculative short-side bets in far greater numbers. I personally view short interest to be considerably high if it amounts to 20% or more of a company's total shares outstanding. But Palantir seems to be thinly shorted by this benchmark. For all we know, its ~3% short interest figure could be comprised of hedging-related bets with the sole purpose of minimizing volatility risk.\nI looked at other software stocks to get a different perspective but to no avail. Out of the 47 stocks in my study, 55% saw their short interest increase while 45% of the stocks registered a decline in their short interest. This more or less even split suggests that market participants wound up their short positions in Palantir largely because of their assessment of the stock and its underlying future prospects, rather than this short covering being driven by industry trends. Besides, shorting activity in Palantir was below industry average, thereby corroborating my view that it's a thinly shorted stock.\nData from individual quote pages on wsj.com\nThis begs the question - why aren't market participants shorting Palantir in the first place?\nCautious for good reason\nFor starters, Palantir's shares corrected by about 45% within February itself as a knee-jerk reaction to its Q4 results. This provided large gains for short-side market participants in a short time span, prompting them to unwind their positions and book healthy profits. So, that's one of the reasons why Palantir's short interest declined in the last cycle.\nData by YCharts\nBesides, with this correction, Palantir's shares are now trading at relatively modest valuation multiples. Per YCharts, its price-to-sales multiple has dropped from a steep 40x in January to a much more reasonable 29.4x at the time of this writing, and the metric is quite close to its 52-week low of around 24x. This suggests that the stock is close to its rock-bottom prices and it might have limited downside potential going forward. So, short-side market participants may be best served by booking profits in Palantir and reallocating their capital in other, more lucrative, trade setups.\nAlso, I explained in my previous article that Palantir is transitioning to a recurring payment model. The company used to charge its customers in advance for multi-year agreements, but it's now going to bill customers on recurring intervals, like a software-as-a-service model but with some contract cancellation clauses. We won't be covering the same points again in this article but the crux of it is that this move is likely going to boost Palantir's commercial revenues. This growth prospect makes it a risky move to short Palantir's shares for the time being, at least.\nAlso, Palantir, historically, hasn't been too focused on its sales effort. Its 10K reads:\n\n …our headcount has grown from 313 full-time employees as of December 31, 2010 to 2,439 full-time employees as of December 31, 2020…\n Our sales force remains relatively small, at about 3% of our total headcount.\n\nI thinkit's needless to say but having an understaffed sales team is bound to limit new order and sales growth. There just wouldn't be enough sales personnel to aggressively chase and convert leads.\nBut Palantir's management seems to be now laser-focused on remedying this oversight by significantly ramping up their sales team. They disclosed last month that the company is gaining access to IBM's 2,500 sellers, which is dramatically up from the current 30 sellers. Its management also noted in their Q4 earnings call that they \"expect to add triple digit head count to our sales function this year\".\nThis heightened focus on revamping the sales function, and their transition to a more customer friendly payment model, is likely going to generate new deals for Palantir and boost its sales along the way. So, in my view, it's risky move to remain short on Palantir for an extended period of time.\nFinal Thoughts\nIf bears truly had a legitimate argument against Palantir, they would have actively shorted the name in a bid to profit off of a potential price correction and we'd have seen a rapid rise in its short interest. But that did not happen and Palantir's short interest dropped significantly instead. This suggests that market participants perceive the stock to be fairly or undervalued, and that the stock may have limited downside potential from the current levels. So, I would recommend Palantir's long-side investors to ignore the fear, uncertainty and doubt, and remain long on the name. Its intensifying sales push and reduced customer resistance with flexible payment plans, are likely going to drive its overall growth going forward. Good Luck!","news_type":1},"isVote":1,"tweetType":1,"viewCount":432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":355319929,"gmtCreate":1617028029861,"gmtModify":1634523037491,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Watch out[惊讶]&nbsp;","listText":"Watch out[惊讶]&nbsp;","text":"Watch out[惊讶]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355319929","repostId":"1180199356","repostType":4,"repost":{"id":"1180199356","pubTimestamp":1617025247,"share":"https://www.laohu8.com/m/news/1180199356?lang=&edition=full","pubTime":"2021-03-29 21:40","market":"us","language":"en","title":"Bank stocks drop after Archegos Capital collapses","url":"https://stock-news.laohu8.com/highlight/detail?id=1180199356","media":"seekingalpha","summary":"Some of the biggest global banks drop in market trading after Archegos Capital, the family office ru","content":"<p>Some of the biggest global banks drop in market trading after Archegos Capital, the family office run by Bill Hwang,wasforced to liquidate, putting the banks in danger of losing billions of dollars.</p><p>Credit Suisse&nbsp;sinks 13%, Nomura&nbsp;slides 13%, Goldman Sachs&nbsp;drops 1%, and Morgan Stanley&nbsp;falls 2.78%, Deutsche Bank&nbsp;dips 2.96%.</p><p><img src=\"https://static.tigerbbs.com/467f28f9b672edc77c3cf438b196dccb\" tg-width=\"279\" tg-height=\"202\" referrerpolicy=\"no-referrer\"></p><p>While it didn't name the client, Credit Suisse&nbsp;warnedinvestors of&nbsp; a \"significant loss\" because it was forced to exit positions after \"a significant U.S.-based hedge fund defaulted on margin calls made last week\" made by CS and a number of other banks, the company said.</p><p>BofA Securities analyst Alastair Ryan downgraded CS to Neutral and reduced his 2021 forecast for the bank and price target due to the losses on the liquidation. \"We believe its capital cushion has likely been reduced to the point where its buyback is directly affected,\" Ryan wrote in a note to clients. (Updated at 7:45 AM ET.)</p><p>Nomura also said it mayincur a significant lossarising from transactions with a U.S. client; it's still calculating its possible loss from the event andestimates the claimagainst the client at ~$2B.</p><p>Morgan Stanley (MS), Goldman Sachs (GS), and Deutsche Bank (DB) are also reported to have been involved. MS and GS didn't immediately respond to request for comment.</p><p>Also see,ViacomCBS block of 45M shares was being offered by Morgan Stanley on Sunday</p><p>Earlier,Morgan Stanley had 'disturbing' widening in credit default swaps late last week, expert says.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bank stocks drop after Archegos Capital collapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBank stocks drop after Archegos Capital collapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-29 21:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3677088-bank-stocks-drop-after-archegos-capital-collapses><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Some of the biggest global banks drop in market trading after Archegos Capital, the family office run by Bill Hwang,wasforced to liquidate, putting the banks in danger of losing billions of dollars....</p>\n\n<a href=\"https://seekingalpha.com/news/3677088-bank-stocks-drop-after-archegos-capital-collapses\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/69af882c29a3ff047224139fe1096d17","relate_stocks":{"MS":"摩根士丹利","NMR":"野村控股","DB":"德意志银行","GS":"高盛"},"source_url":"https://seekingalpha.com/news/3677088-bank-stocks-drop-after-archegos-capital-collapses","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1180199356","content_text":"Some of the biggest global banks drop in market trading after Archegos Capital, the family office run by Bill Hwang,wasforced to liquidate, putting the banks in danger of losing billions of dollars.Credit Suisse sinks 13%, Nomura slides 13%, Goldman Sachs drops 1%, and Morgan Stanley falls 2.78%, Deutsche Bank dips 2.96%.While it didn't name the client, Credit Suisse warnedinvestors of  a \"significant loss\" because it was forced to exit positions after \"a significant U.S.-based hedge fund defaulted on margin calls made last week\" made by CS and a number of other banks, the company said.BofA Securities analyst Alastair Ryan downgraded CS to Neutral and reduced his 2021 forecast for the bank and price target due to the losses on the liquidation. \"We believe its capital cushion has likely been reduced to the point where its buyback is directly affected,\" Ryan wrote in a note to clients. (Updated at 7:45 AM ET.)Nomura also said it mayincur a significant lossarising from transactions with a U.S. client; it's still calculating its possible loss from the event andestimates the claimagainst the client at ~$2B.Morgan Stanley (MS), Goldman Sachs (GS), and Deutsche Bank (DB) are also reported to have been involved. MS and GS didn't immediately respond to request for comment.Also see,ViacomCBS block of 45M shares was being offered by Morgan Stanley on SundayEarlier,Morgan Stanley had 'disturbing' widening in credit default swaps late last week, expert says.","news_type":1},"isVote":1,"tweetType":1,"viewCount":298,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":353002920,"gmtCreate":1616427559060,"gmtModify":1634525858287,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[保佑]&nbsp;[思考]&nbsp;","listText":"[保佑]&nbsp;[思考]&nbsp;","text":"[保佑] [思考]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/353002920","repostId":"353000812","repostType":1,"isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":363900841,"gmtCreate":1614088374883,"gmtModify":1634551229883,"author":{"id":"3574494955430053","authorId":"3574494955430053","name":"teokb989","avatar":"https://static.tigerbbs.com/630844e6a5d93f0d91171ccff58a4fcf","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/363900841","repostId":"2113335786","repostType":2,"repost":{"id":"2113335786","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1614083671,"share":"https://www.laohu8.com/m/news/2113335786?lang=&edition=full","pubTime":"2021-02-23 20:34","market":"us","language":"en","title":"BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2113335786","media":"Reuters","summary":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DES","content":"<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-European Commission Grants Ocugen Orphan Medicinal Product Designation For Gene Therapy Product Candidate, Ocu400, For The Treatment Of Both Retinitis Pigmentosa And Leber Congenital Amaurosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-23 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 23 (Reuters) - Ocugen Inc   :</p><p>   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2113335786","content_text":"Feb 23 (Reuters) - Ocugen Inc   :   * EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSISSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":574,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}